NextCure, Inc. (NXTC) research

NextCure, Inc.

Sector: Healthcare
Industry: Biotechnology
Last price: $5.09
As of: 2026-10-02

NextCure, Inc. (NXTC): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-25.

As of 2026-09-25, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for NXTC. Method and limitations.

COMPANY DOSSIER

See the full NXTC dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for NXTC on one page. Preview it with sample data, then open it live with a free account.

Preview the NXTC dossier

Active signals for NXTC

highINSTITUTIONAL_SURGE2026-08-16
MILLENNIUM MANAGEMENT LLC added +576% to NXTC (2026Q2)
All 2026-08-16 signals →
highINSTITUTIONAL_SURGE2026-08-16
RENAISSANCE TECHNOLOGIES LLC added +183% to NXTC (2026Q2)
All 2026-08-16 signals →
mediumEARNINGS_MISS2026-08-12
Q2-2026: Missed consensus by 42.1%, EPS $-2.80 vs $-1.971 estimate
All 2026-08-12 signals →
highINSTITUTIONAL_SURGE2026-07-24
RENAISSANCE TECHNOLOGIES LLC added +80% to NXTC (2026Q1)
All 2026-07-24 signals →
mediumEARNINGS_BEAT2026-06-19
Q3-2025: Beat consensus by 20.7% - EPS $-3.22 vs $-4.063 estimate
All 2026-06-19 signals →

FREE, NO ACCOUNT

Every signal on NXTC, as it fires

You are seeing 5 of 10 signals recorded on NXTC since 2026-05-31.

The five above landed across 4 days. The other 5 were recorded on 1 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in NXTC (2026Q2)

Manager / security	Market value	% portfolio	QoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 65343E207 · 2026Q2	$274K	0.00%	,
MILLENNIUM MANAGEMENT LLCCUSIP 65343E207 · 2026Q2	$141K	0.00%	,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, NXTC

8-K2026-09-25
SEC EDGAR ↗
8-K2026-09-03
SEC EDGAR ↗
8-K2026-08-06
SEC EDGAR ↗
10-Q2026-08-06
SEC EDGAR ↗
8-K2026-07-14
SEC EDGAR ↗
8-K2026-06-25
SEC EDGAR ↗
8-K2026-06-01
SEC EDGAR ↗
8-K2026-05-07
SEC EDGAR ↗
10-Q2026-05-07
SEC EDGAR ↗
8-K2026-03-05
SEC EDGAR ↗

NXTC against its peers

NXTC's return on equity of -159.8% ranks in the 32nd percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

Metric	NXTC	Peer median	Percentile	n
Revenue FY	n/a	872083	n/a	8
Operating margin	n/a	-1402.2%	n/a	8
Net margin	n/a	-1404.4%	n/a	8
Return on equity	-159.8%	-95.4%	32	13

Peers (15): COCP, TCRX, PVCT, GRDX, JSPR, HOTH, PSTV, LONA, NEUP, ATOS, KYNB, ABVC, AKTX, VYNE, CNTX. Left out: RADX (no annual filing), SEOVF (no annual filing), PLRZ (no annual filing), PBM (period gap), VICP (period gap), QNTM (no annual filing), TTIPF (no annual filing), MDNAF (no annual filing), CLCS (period gap), IGC (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NXTC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more NXTC signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NXTCand get the insider, 13F, options, and confluence read in one view.